Back to CITADEL ADVISORS LLC

LXEO
Showing 8 of 10 quarters

Position history for CITADEL ADVISORS LLC's holdings in LEXEO THERAPEUTICS INC

CITADEL ADVISORS LLC holds 3.8M shares of LXEO (LEXEO THERAPEUTICS INC), worth $22M as of 2026-Q1. The position was increased (+1.6% shares). LXEO represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$22M

Current Shares

3.8M

Total Value Change

-$19M

Total Shares Change

+1.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
3.8M
+1.6%
$22M0.0%$7.07
29
2025-Q4
Increased
3.8M
+1.5%
$37.5M0.0%$9.74
29
2025-Q3
Increased
3.7M
+3.1%
$24.7M0.0%$6.66
29
2025-Q2
Increased
3.6M
+32.5%
$14.5M0.0%$4.12
36
2025-Q1
Unchanged
2.7M
0.0%
$9.5M0.0%$4.10
0
2024-Q4
Unchanged
2.7M
0.0%
$17.9M0.0%$6.54
0
2024-Q3
Increased
2.7M
+6.4%
$24.6M0.0%$9.11
31
2024-Q2
Increased
2.6M
+2.2%
$41M0.0%$16.04
30

Other major holders of LXEO: Janus Henderson Group Ltd., RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used